Moderna Pharmaceuticals

Moderna Stock Falls

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Business Insider · 22h

Moderna downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance

MarketWatch on MSN · 17h

Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

ca.investing.com on MSN · 16h

Moderna stock drops as Goldman Sachs cuts rating

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs (NYSE:GS) cut its rating on the stock to Neutral from Buy.

Seeking Alpha on MSN · 18h

Moderna down as Goldman Sachs downgrades on revenue outlook

Moderna (NASDAQ:MRNA) traded lower in the premarket on Wednesday after Goldman Sachs downgraded the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Goldman's downgrade comes days after the Cambridge,

14h

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Hosted on MSN2d

Here's What to Expect From Moderna's Next Earnings Report

Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

Reuters17d

Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble

Moderna has only two products in the market ... Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur Sriparna reports on pharmaceutical companies and healthcare in the United States.

19h

Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Where Will Moderna Be in 3 Years?

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

dermatologyadvisor2d

Moderna Receives $590M From HHS to Develop Bird Flu Vaccine

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

FiercePharma2d

Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

10don MSN

Is Moderna Stock a Buy?

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

CNN3y

Moderna, Inc.

Moderna, Inc. engages in the development of ... localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.

Forbes10mon

How Moderna Is Embracing Data & AI To Transform Drug Discovery

nowhere are the life and death consequences so great as in the worlds of pharmaceuticals, biotech, and medicine. Just ask Brad Miller, Chief Information Officer (CIO) of Moderna. Brad is ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results